Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream

Miki Shirakawa Garcia, Yoko Ono, Steve R. Martinez, Steven L. Chen, Heidi Goodarzi, Tiffany Phan, Lisa N. Wehrli, Yoshinori Miyamura, Maxwell A Fung, Emanual Michael Maverakis

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

There are limited treatment options for metastatic melanoma, which is almost universally fatal. We report the successful treatment of 64 of 64 cutaneous and subcutaneous melanoma metastases in three patients using high-dose (22 million units per 1.2 ml) intralesional interleukin 2 (IL-2) in combination with topical imiquimod and a retinoid cream. Before intralesional therapy, all patients had been treated surgically and were no longer considered surgical candidates. Rebiopsy of 15 of the treatment sites and long-term follow-up (10, 12, and 27 months) showed regression of all treated tumors. Six months after discontinuation of therapy, one patient developed multiple new cutaneous metastases, but these were also responsive to treatment with intralesional therapy. The other two patients did not experience recurrence of their cutaneous melanoma. However, one of the two patients developed lymph node and brain metastases 18 months after initiation of intralesional therapy, but is still alive, now at 27 months. The concentration of IL-2 used for the intralesional therapy was much higher than in previously reported cases, which may explain the excellent responses that were observed. These results support intralesional high-dose IL-2 as a very effective therapy for controlling cutaneous metastatic melanoma. Additional studies are needed to determine whether this therapy is associated with a survival benefit.

Original languageEnglish (US)
Pages (from-to)235-243
Number of pages9
JournalMelanoma Research
Volume21
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

imiquimod
Retinoids
Interleukin-2
Melanoma
Skin
Therapeutics
Neoplasm Metastasis

Keywords

  • imiquimod
  • immunotherapy
  • inflammation
  • interleukin 2
  • intralesional therapy
  • melanoma
  • retinoic acid
  • toll-like receptors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Cite this

Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. / Garcia, Miki Shirakawa; Ono, Yoko; Martinez, Steve R.; Chen, Steven L.; Goodarzi, Heidi; Phan, Tiffany; Wehrli, Lisa N.; Miyamura, Yoshinori; Fung, Maxwell A; Maverakis, Emanual Michael.

In: Melanoma Research, Vol. 21, No. 3, 06.2011, p. 235-243.

Research output: Contribution to journalArticle

Garcia, Miki Shirakawa ; Ono, Yoko ; Martinez, Steve R. ; Chen, Steven L. ; Goodarzi, Heidi ; Phan, Tiffany ; Wehrli, Lisa N. ; Miyamura, Yoshinori ; Fung, Maxwell A ; Maverakis, Emanual Michael. / Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. In: Melanoma Research. 2011 ; Vol. 21, No. 3. pp. 235-243.
@article{9f93d9f311f24412a490fdc8a5b252a7,
title = "Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream",
abstract = "There are limited treatment options for metastatic melanoma, which is almost universally fatal. We report the successful treatment of 64 of 64 cutaneous and subcutaneous melanoma metastases in three patients using high-dose (22 million units per 1.2 ml) intralesional interleukin 2 (IL-2) in combination with topical imiquimod and a retinoid cream. Before intralesional therapy, all patients had been treated surgically and were no longer considered surgical candidates. Rebiopsy of 15 of the treatment sites and long-term follow-up (10, 12, and 27 months) showed regression of all treated tumors. Six months after discontinuation of therapy, one patient developed multiple new cutaneous metastases, but these were also responsive to treatment with intralesional therapy. The other two patients did not experience recurrence of their cutaneous melanoma. However, one of the two patients developed lymph node and brain metastases 18 months after initiation of intralesional therapy, but is still alive, now at 27 months. The concentration of IL-2 used for the intralesional therapy was much higher than in previously reported cases, which may explain the excellent responses that were observed. These results support intralesional high-dose IL-2 as a very effective therapy for controlling cutaneous metastatic melanoma. Additional studies are needed to determine whether this therapy is associated with a survival benefit.",
keywords = "imiquimod, immunotherapy, inflammation, interleukin 2, intralesional therapy, melanoma, retinoic acid, toll-like receptors",
author = "Garcia, {Miki Shirakawa} and Yoko Ono and Martinez, {Steve R.} and Chen, {Steven L.} and Heidi Goodarzi and Tiffany Phan and Wehrli, {Lisa N.} and Yoshinori Miyamura and Fung, {Maxwell A} and Maverakis, {Emanual Michael}",
year = "2011",
month = "6",
doi = "10.1097/CMR.0b013e328345e95e",
language = "English (US)",
volume = "21",
pages = "235--243",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream

AU - Garcia, Miki Shirakawa

AU - Ono, Yoko

AU - Martinez, Steve R.

AU - Chen, Steven L.

AU - Goodarzi, Heidi

AU - Phan, Tiffany

AU - Wehrli, Lisa N.

AU - Miyamura, Yoshinori

AU - Fung, Maxwell A

AU - Maverakis, Emanual Michael

PY - 2011/6

Y1 - 2011/6

N2 - There are limited treatment options for metastatic melanoma, which is almost universally fatal. We report the successful treatment of 64 of 64 cutaneous and subcutaneous melanoma metastases in three patients using high-dose (22 million units per 1.2 ml) intralesional interleukin 2 (IL-2) in combination with topical imiquimod and a retinoid cream. Before intralesional therapy, all patients had been treated surgically and were no longer considered surgical candidates. Rebiopsy of 15 of the treatment sites and long-term follow-up (10, 12, and 27 months) showed regression of all treated tumors. Six months after discontinuation of therapy, one patient developed multiple new cutaneous metastases, but these were also responsive to treatment with intralesional therapy. The other two patients did not experience recurrence of their cutaneous melanoma. However, one of the two patients developed lymph node and brain metastases 18 months after initiation of intralesional therapy, but is still alive, now at 27 months. The concentration of IL-2 used for the intralesional therapy was much higher than in previously reported cases, which may explain the excellent responses that were observed. These results support intralesional high-dose IL-2 as a very effective therapy for controlling cutaneous metastatic melanoma. Additional studies are needed to determine whether this therapy is associated with a survival benefit.

AB - There are limited treatment options for metastatic melanoma, which is almost universally fatal. We report the successful treatment of 64 of 64 cutaneous and subcutaneous melanoma metastases in three patients using high-dose (22 million units per 1.2 ml) intralesional interleukin 2 (IL-2) in combination with topical imiquimod and a retinoid cream. Before intralesional therapy, all patients had been treated surgically and were no longer considered surgical candidates. Rebiopsy of 15 of the treatment sites and long-term follow-up (10, 12, and 27 months) showed regression of all treated tumors. Six months after discontinuation of therapy, one patient developed multiple new cutaneous metastases, but these were also responsive to treatment with intralesional therapy. The other two patients did not experience recurrence of their cutaneous melanoma. However, one of the two patients developed lymph node and brain metastases 18 months after initiation of intralesional therapy, but is still alive, now at 27 months. The concentration of IL-2 used for the intralesional therapy was much higher than in previously reported cases, which may explain the excellent responses that were observed. These results support intralesional high-dose IL-2 as a very effective therapy for controlling cutaneous metastatic melanoma. Additional studies are needed to determine whether this therapy is associated with a survival benefit.

KW - imiquimod

KW - immunotherapy

KW - inflammation

KW - interleukin 2

KW - intralesional therapy

KW - melanoma

KW - retinoic acid

KW - toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=79955592285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955592285&partnerID=8YFLogxK

U2 - 10.1097/CMR.0b013e328345e95e

DO - 10.1097/CMR.0b013e328345e95e

M3 - Article

C2 - 21464773

AN - SCOPUS:79955592285

VL - 21

SP - 235

EP - 243

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 3

ER -